Published in Medical Letter on the CDC and FDA, March 17th, 2002
European health officials report 25 similar cases of liver toxicity, and some countries are barring kava sales. Now the U.S. Food and Drug Administration (FDA) is investigating whether the herbal sedative - promoted to relieve anxiety, stress and insomnia - poses a danger.
Under review are 38 Americans, including the transplant recipient, with medical problems possibly associated with kava use. FDA scientists cannot yet say if the blockbuster seller is to blame.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.